Tumor suppressor gene PTEN mutations are observed to be co-expressed with BRAF mutations in patients harboring BRAF mutations, contributing to immune escape of tumor cells through various mechanisms unrelated to the MAPK pathway, including downregulation of the tumor microenvironment and antitumoral immune cells within tertiary lymphoid structures. This evidence concerns the gene PTEN and neoplasm.